Todd C. Davis
Chief Executive Officer & Director @ Ligand Pharmaceuticals
Jupiter, United States
Todd C. Davis is a funding round investor at Ligand Pharmaceuticals in Jupiter focused on Biopharma and Life Science. Todd Davis is the Chief Executive Officer & Director of Ligand Pharmaceuticals. He previously worked at BioDelivery Sciences International as a Director. Todd Davis attended Harvard Business School.
- Total investments:
- 1
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Todd C. Davis invests in
Stages Todd C. Davis invests in
Countries Todd C. Davis invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biopharma 1 (100%)
- Life Science 1 (100%)
- Biotechnology 1 (100%)
- Pharmaceutical 1 (100%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Castle Creek Biosciences is focused on developing and commercializing novel, personalized gene therapies for rare skin and connective tissue disorders with high unmet need. It was founded in 2015 and headquartered in Pennsylvania, United States. | $75M |
About Ligand Pharmaceuticals
Ligand is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Ligand business model creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Ligand's goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified, and lower-risk business than a typical biotech company. Ligand business model is based on doing what we do best: drug discovery, early-stage drug development, product reformulation, and partnering. Ligand partner with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management, and commercialization) to ultimately generate Ligand revenue.
Ligand Pharmaceuticals Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Bob Chen
Director, Systems Engineering and Site Head
|
|||
|
David J. Mangelsdorf
Team Member
|
|||
John Higgins
CEO
|
|||
Richard Baxter
Senior Vice President of Investment Operations
|
|||
|
Todd C. Davis
Chief Executive Officer & Director
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Todd C. Davis invest in?
Todd C. Davis invests primarily in Biopharma, Life Science and Biotechnology startups, most often at Funding Round stage. Most of the 1 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Todd C. Davis?
Public channels for Todd C. Davis include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Nov 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
